About Activator of 90 kDa heat shock protein ATPase homolog 1
Activator of 90 kDa heat shock protein ATPase homolog 1 (AHSA1) is a protein
from Homo sapiens identified by UniProt accession
O95433, 338 residues long.
MolForge cross-references it against 0 known binders and
59 disease associations.
Target properties
| Protein name | Activator of 90 kDa heat shock protein ATPase homolog 1 |
| UniProt accession | O95433 |
| Gene | AHSA1 |
| Organism | Homo sapiens |
| Length | 338 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (59)
Diseases linked to this target (Open Targets).
- leukocyte count · score 0.15
- lymphocyte percentage of leukocytes · score 0.12
- apolipoprotein A 1 measurement · score 0.11
- hepatocellular carcinoma · score 0.10
- neoplasm · score 0.09
- eosinophil count · score 0.09
- Miyoshi myopathy · score 0.08
- retinitis pigmentosa · score 0.07
- neutrophil percentage of leukocytes · score 0.06
- myeloid white cell count · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95433-F1 | alphafold | PREDICTED | 80.75 | — |
Amino-acid sequence (338 residues)
MAKWGEGDPR WIVEERADAT NVNNWHWTER DASNWSTDKL KTLFLAVQVQ NEEGKCEVTE VSKLDGEASI NNRKGKLIFF YEWSVKLNWT GTSKSGVQYK GHVEIPNLSD ENSVDEVEIS VSLAKDEPDT NLVALMKEEG VKLLREAMGI YISTLKTEFT QGMILPTMNG ESVDPVGQPA LKTEERKAKP APSKTQARPV GVKIPTCKIT LKETFLTSPE ELYRVFTTQE LVQAFTHAPA TLEADRGGKF HMVDGNVSGE FTDLVPEKHI VMKWRFKSWP EGHFATITLT FIDKNGETEL CMEGRGIPAP EEERTRQGWQ RYYFEGIKQT FGYGARLF
Explore Activator of 90 kDa heat shock protein ATPase homolog 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets